Photo from wikipedia
Patients on maintenance haemodialysis are prone to severe coronavirus disease 2019 (COVID-19) and have a high case fatality rate. Vaccination is a promising strategy to reduce mortality and morbidity. Most… Click to show full abstract
Patients on maintenance haemodialysis are prone to severe coronavirus disease 2019 (COVID-19) and have a high case fatality rate. Vaccination is a promising strategy to reduce mortality and morbidity. Most published data are available for the adenovirus-vector ChAdOx1 nCoV-19/AZD1222 (AstraZeneca) and the mRNA-based vaccines [BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)] [1, 2]. dialysis patients remain a population. Patients receiving dialysis have a poorer antibody response rate as compared with individuals not receiving dialysis Factors determining response include severe respiratory syndrome coronavirus (SARS-CoV-2) and comorbidities, e.g. diabetes. The prevalence of absent or diminished antibody response
Journal Title: Nephrology Dialysis Transplantation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!